SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript
SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT Company Participants Angelos Stergiou - Founder, President, CEO & Director Dragan Cicic - Senior VP & Chief Development Officer Conference Call Participants Dr. Omer Jamy Dr. Panagiotis Tsirigotis Dr. Philip M. Ryan Sharif Khan, M.D.
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML applicability. GPS's REGAL final analysis at 80 events expected should come by year-end 2025. Its prior data suggest survival advantages versus historical controls.
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galena Biopharma (SLS) Upgraded to Buy: Here's Why
Galena Biopharma (SLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
